Tel: 859-242-7836
TELEHEALTH
Wegovy (Semaglutide):
Wegovy® (semaglutide) is an FDA-approved GLP-1 medication for chronic weight management in adults with obesity or overweight and related health conditions.
It is not appropriate for patients with a personal or family history of medullary thyroid carcinoma or MEN2.
​
Customized compounded semaglutide is available for certain patients and conditions. Compounded medications are prepared by licensed U.S. compounding pharmacies under prescription from a licensed clinician.
They are not FDA-approved products but are compounded in compliance with federal and state regulations to meet individual patient needs.
Our practice partners only with pharmacies that provide third-party sterility and potency testing for every batch.
​
Wegovy® is a registered trademark of Novo Nordisk A/S. Our telehealth practice is independently owned and not affiliated with Novo Nordisk.
Indications:
​
Chronic Weight Management (Obesity / Overweight)
Wegovy® (semaglutide) is FDA-approved as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol.
Cardiovascular Risk Reduction
Wegovy® (semaglutide) is FDA-approved to reduce the risk of major cardiovascular events — such as heart attack, stroke, or cardiovascular death — in adults with established cardiovascular disease (CVD) who are overweight or have obesity.
In clinical trials, Wegovy significantly lowered the risk of heart attack and stroke in adults with obesity and existing heart disease.
Metabolic-Associated Steatohepatitis (MASH / Fatty Liver Disease)
Wegovy® (semaglutide) is FDA-approved for the treatment of adults with metabolic-associated steatohepatitis (MASH) — also known as fatty liver disease — with liver fibrosis stages F1 to F3.
Wegovy has been shown to improve liver inflammation, reduce fat buildup, and slow fibrosis progression in adults with MASH and obesity.